Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4553-4561

  Cao, Ming Yu ^a   Lee, Yoon ^a   Feng, Ning Ping ^a   Xiong, Keyong ^a   Jin, Hongnan ^a   Wang, Ming ^a   Vassilakos, Aikaterini ^a   Viau, Stéphane ^a   Wright, Jim A ^a   Young, Aiping H ^a  

^a Lorus Therapeutics Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY RNA; DNA; MESSENGER RNA; POLYPEPTIDE; RIBONUCLEOTIDE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE R1; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CATALYSIS; CELL GROWTH; COLON CARCINOMA; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VIRAL GENE THERAPY; VIRUS RECOMBINANT; XENOGRAFT;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; BLOTTING, NORTHERN; COLONIC NEOPLASMS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; RIBONUCLEOTIDE REDUCTASES; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 10744222070     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin., 50: 7-33, 2000.
2. Chow, W. H., Devesa, S. S., Warren, J. L., and Fraumeni, J. F., Jr. Rising incidence of renal cell cancer in the United States. JAMA., 281: 1628-1631, 1999.
3. Wadhwa, P. D., Zielske, S. P., Roth, J. C., Ballas, C. B., Bowman, J. E., and Gerson, S. L. Cancer gene therapy: scientific basis. Annu. Rev. Med., 53: 437-452, 2002.
4. Thelander, L., and Reichard, P. Reduction of ribonucleotides. Annu. Rev. Biochem., 48: 133-158, 1979.
5. Reichard, P. Ribonucleotide reductases: the evolution of allosteric regulation. Arch. Biochem. Biophys., 397: 149-155, 2002.
6. Nocentini, G. Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Crit. Rev. Oncol. Hematol., 22: 89-126, 1996.
7. Fan, H., Huang, A., Villegas, C., and Wright, J. A. The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc. Natl. Acad. Sci. USA, 94: 13181-13186, 1997.
8. Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., and Nakamura, Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature (Lond.), 404: 42-49. 2000.
9. Nakano, K., Balint, E., Ashcroft, M., and Vousden, K. H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene, 19: 4283-4289, 2000.
10. Yamaguchi, T., Matsuda, K., Sagiya, Y., Iwadate, M., Fujino, M. A., Nakamura, Y., and Arakawa, H. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res., 61: 8256-8262, 2001.
11. Guittet, O., Hakansson, P., Voevodskaya, N., Fridd, S., Graslund, A., Arakawa, H., Nakamura, Y., and Thelander, L. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J. Biol. Chem., 276: 40647-51, 2001.
12. Yang-Feng, T. L., Barton, D. E., Thelander, L., Lewis, W. H., Srinivasan, P. R., and Francke, U. Ribonucleotide reductase M2 subunit sequences mapped to four different chromosomal sites in humans and mice: functional locus identified by its amplification in hydroxyurea-resistant cell lines. Genomics, 1: 77-86, 1987.
13. Bepler, G., Gautam, A., McIntyre, L. M., Beck, A. F., Chervinsky, D. S., Kim, Y. C., Pitterle, D. M., and Hyland, A. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J. Clin. Oncol., 20: 1353-1360, 2002.
14. Bepler, G., and Garcia-Blanco, M. A. Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer, Proc. Natl. Acad. Sci. USA, 91: 5513-5517, 1994.
15. Tran, Y. K., and Newsham, I. F. High-density marker analysis of 11p15.5 in non-small cell lung carcinomas reveals allelic deletion of one shared and one distinct region when compared to breast carcinomas. Cancer Res., 56: 2916-2921, 1996.
16. Ali, I. U., Lidereau, R., Theillet, C., and Callahan, R. Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science (Wash. DC), 238: 185-188, 1987.
17. Viel, A., Giannini, F., Tumiotto, L., Sopracordevole, F., Visentin, M. C., and Boiocchi, M. Chromosomal localisation of two putative 11p oncosuppressor genes involved in human ovarian tumours. Br. J. Cancer, 66: 1030-1036, 1992.
18. Ranzani, G. N., Renault, B., Pellegata, N. S., Fattorini, P., Magni, E., Bacci, F., and Amadori, D. Loss of heterozygosity and K-ras gene mutations in gastric cancer. Hum. Genet., 92: 244-249, 1993.
19. Karnik, P., Paris, M., Williams, B. R., Casey, G., Crowe, J., and Chen, P. Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastasis. Hum. Mol. Genet., 7: 895-903, 1998.
20. Bepler, G., Fong, K. M., Johnson, B. E., O'Briant, K. C., Daly, L. A., Zimmerman, P. V., Garcia-Blanco, M. A., and Peterson, B. Association of chromosome 11 locus D11S12 with histology, stage, and metastases in lung cancer. Cancer Detect. Prev., 22: 14-19, 1998.
21. Pitterle, D. M., Kim, Y. C., Jolicoeur, E. M., Cao, Y., O'Briant, K. C., and Bepler, G. Lung cancer and the human gene for ribonucleotide reductase subunit MI (RRM1). Mamm. Genome, 10: 916-922, 1999.
22. O'Briant, K. C., and Bepler, G. Delineation of the centromeric and telomeric chromosome segment 11p15.5 lung cancer suppressor regions LOH11A and LOH11B. Genes Chromosomes Cancer, 18: 111-114, 1997.
23. Srivatsan, E. S., Benedict, W. F., and Stanbridge, E. J. Implication of chromosome 11 in the suppression of neoplastic expression in human cell hybrids. Cancer Res., 46: 6174-6179, 1986.
24. Koi, M., Johnson, L. A., Kalikin, L. M., Little, P. F., Nakamura, Y., and Feinberg, A. P. Tumor cell growth arrest caused by subchromosomal transferable DNA fragments from chromosome 11. Science (Wash. DC), 260: 361-364, 1993.
25. Phillips, K. K., Welch, D. R., Miele, M. E., Lee, J. H., Wei, L. L., and Weissman, B. E. Suppression of MDA-MB-435 breast carcinoma cell metastasis following the introduction of human chromosome 11. Cancer Res., 56: 1222-1227, 1996.
26. Reid, L. H., West, A., Gioeli, D. G., Phillips, K. K., Kelleher, K. F., Araujo, D., Stanbridge, E. J., Dowdy, S. F., Gerhard, D. S., and Weissman, B. E. Localization of a tumor suppressor gene in 11p15.5 using the G401 Wilms' tumor assay. Hum. Mol. Genet., 5: 239-247, 1996.
27. O'Briant, K., Jolicoeur, E., Garst, J., Campa, M., Schreiber, G., and Bepler, G. Growth inhibition of a human lung adenocarcinoma cell line by genetic complementation with chromosome 11. Anticancer Res., 17: 3243-3251, 1997.
28. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36: 59-74, 1977.
29. Ng, P., Cummings, D. T., Evelegh, C. M., and Graham, F. L. Yeast recombinase FLP functions effectively in human cells for construction of adenovirus vectors. Biotechniques, 29: 524-528, 2000.
30. Ng, P., Parks, R. J., Cummings, D. T., Evelegh, C. M., Sankar, U., and Graham, F. L. A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum. Gene Ther., 10: 2667-2672, 1999.
31. Brody, S. L., and Crystal, R. G. Adenovirus-mediated in vivo gene transfer. Ann. N. Y. Acad. Sci., 716: 90-101; discussion 101-3, 1994.
32. Vorburger, S. A., and Hunt, K. K. Adenoviral gene therapy. Oncologist, 7: 46-59, 2002.
33. Spitz, F. R., Nguyen, D., Skibber, J. M., Cusack, J., Roth, J. A., and Cristiano, R. J. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res., 16: 3415-3422, 1996.
34. Ko, S. C., Gotoh, A., Thalmann, G. N., Zhau, H. E., Johnston, D. A., Zhang, W. W., Kao, C., and Chung, L. W. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum. Gene Ther., 7: 1683-1691, 1996.
35. Nielsen, L. L., Dell, J., Maxwell, E., Armstrong, L., Maneval, D., and Catino, J. J. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther., 4: 129-138, 1997.
36. Hamada, K., Zhang, W. W., Alemany, R., Wolf, J., Roth, J. A., and Mitchell, M. F. Growth inhibition of human cervical cancer cells with the recombinant adenovirus p53 in vitro. Gynecol. Oncol., 60: 373-379, 1996.
37. Mujoo, K., Maneval, D. C., Anderson, S. C., and Gutterman, J. U. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene, 12: 1617-1623, 1996.
38. Cirielli, C., Riccioni, T., Yang, C., Pili, R., Gloe, T., Chang, J., Inyaku, K., Passaniti, A., and Capogrossi, M. C. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int. J. Cancer, 63: 673-679, 1995.
39. Fan, H., Villegas, C., and Wright, J. A. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential, Proc. Natl. Acad. Sci. USA, 93: 14036-40, 1996.
40. Zhao, B., and Bepler, G. Transcript map and complete genomic sequence for the 310 kb region of minimal allele loss on chromosome segment 11p15.5 in non-small-cell lung cancer. Oncogene, 20: 8154-8164, 2001.
41. Knudson, A. G., Jr. Mutation and cancer: statistical study of retinoblastoma, Proc. Natl. Acad. Sci. USA, 68: 820-823, 1971.
42. Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., and Kemp, C. J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature (Lond.), 396: 177-180, 1998.
43. Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L. H., Broudy, V., Perlmutter, R. M., Kaushansky, K., and Roberts, J. M. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell, 85: 733-744, 1996.
44. Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., and Koff, A. p27Kip1. a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
45. Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M. H., Massague, J., Crabtree, G. R., and Roberts, J. M. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (Lond.), 372: 570-573, 1994.
46. 1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell, 79: 487-496, 1994.
47. Coats, S., Flanagan, W. M., Nourse, J., and Roberts, J. M. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science (Wash. DC), 272: 877-880, 1996.
48. Hurta, R. A., Samuel, S. K., Greenberg, A. H., and Wright, J. A. Early induction of ribonucleotide reductase gene expression by transforming growth factor β1 in malignant H-ras transformed cell lines. J. Biol. Chem., 266: 24097-100, 1991.
49. Zhou, B. S., Hsu, N. Y., Pan, B. C., Doroshow, J. H., and Yen, Y. Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res., 55: 1328-1333, 1995.
50. Bjorklund, S., Skog, S., Tribukait, B., and Thelander, L. S-phasespecific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. Biochemistry, 29: 5452-5458, 1990.
51. Eriksson, S., Graslund, A., Skog, S., Thelander, L., and Tribukait, B. Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis, J. Biol. Chem., 259: 11695-700, 1984.
52. Engstrom, Y., Eriksson, S., Jildevik, I., Skog, S., Thelander, L., and Tribukait, B. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits, J. Biol. Chem., 260: 9114-9116, 1985.
53. Chabes, A., and Thelander, L. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J. Biol. Chem., 275: 17747-17753, 2000.
54. Mann, G. J., Musgrove, E. A., Fox, R. M., and Thelander, L. Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res., 48: 5151-5156, 1988.
55. Zhou, B. S., Tsai, P., Ker, R., Tsai, J., Ho, R., Yu, J., Shih, J., and Yen, Y. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin. Exp. Metastasis, 16: 43-49, 1998.